Here, we found that NTN3 transcription is positively regulated by both EZH2 and AR in prostate cancer (r = 0.2297 and 0.2863, respectively)(Fig. 6b), suggesting that NTN3 may play a oncogenic role in prostate cancer. This evidence concerns the gene EZH2 and prostate carcinoma.